WARF: P00331US

  • Assigned to WARF as biological material.

Transgenic Mouse for Testing Chemotherapeutic Agents


Mary Ellen Perry, Susan Mendrysa

The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in transgenic mice that are conditional knockouts for mdm2.
OVERVIEWThe gene mdm2 is a negative regulator of p53, which plays a key role in apoptosis and is important in chemotherapy. Mice with knockout mutations in mdm2 would be useful in studying this gene; however, mdm2 is also essential for embryonic development.
THE INVENTIONUW-Madison researchers have developed transgenic mice that are conditional knockouts for mdm2. In these mice, exons 7-9 of the mdm2 gene are flanked with a particular sequence. When exposed to a specific recombinase, these exons should be deleted, rendering the gene non-functional.
  • Mice may be useful for testing chemotherapeutic agents.
  • Murine embryonic fibroblasts (MEFs) from the mice may also be useful for testing chemotherapeutic agents.
  • MEFs could be used as positive controls in assays to screen for compounds that interfere with the mdm2/p53 interaction.
  • Knockout mutations can be tissue specific.
Contact Information
For current licensing status, please contact Jennifer Gottwald at or 608-960-9854.
The WARF Advantage

Since its founding in 1925 as the patenting and licensing organization for the University of Wisconsin-Madison, WARF has been working with business and industry to transform university research into products that benefit society. WARF intellectual property managers and licensing staff members are leaders in the field of university-based technology transfer. They are familiar with the intricacies of patenting, have worked with researchers in relevant disciplines, understand industries and markets, and have negotiated innovative licensing strategies to meet the individual needs of business clients.